Related Experiment Video

Updated: Feb 18, 2026

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn
11:27

A Modified Sonographic Algorithm for Image Acquisition in Life-Threatening Emergencies in the Critically Ill Newborn

Published on: April 7, 2023

7.5K

Antithrombotic treatment in neonates and children

C Heleen van Ommen1

  • 1Department of Pediatric Hematology, Sophia Children's Hospital ErasmusMC, Rotterdam, The Netherlands - c.vanommen@erasmusmc.nl.

Minerva Pediatrica
|November 22, 2017
PubMed

Insights

Pediatric venous thromboembolism, though rare, affects neonates and adolescents. Management strategies for childhood thrombosis require careful consideration due to developmental hemostasis differences from adults.

Area of Science:

  • Pediatric Hematology
  • Neonatal Medicine
  • Pediatric Thrombosis

Background:

  • Venous thromboembolic disease is increasingly recognized in pediatric patients, though still rare.
  • Neonates and adolescents represent high-risk groups for venous thrombosis.
  • Common risk factors include central venous catheters, congenital heart disease, infection, malignancy, and surgery.

Purpose of the Study:

  • To review the management of venous thrombosis in neonates and children.
  • To discuss the application of antithrombotic agents in pediatric populations.
  • To highlight differences in developmental hemostasis between children and adults.

Main Methods:

  • Literature review focusing on pediatric venous thrombosis.
  • Analysis of existing recommendations for antithrombotic therapy.
  • Comparison of pediatric and adult hemostatic systems.

Main Results:

  • Ultrasonography is the primary diagnostic tool for pediatric thrombi.
  • Most pediatric thrombotic events occur in patients with multiple risk factors.
  • Current management guidelines are often based on adult data, overlooking pediatric-specific factors.

Conclusions:

  • Effective management of pediatric venous thrombosis necessitates tailored approaches.
  • Antithrombotic therapy in children must account for developmental hemostasis.
  • Further research is needed to establish pediatric-specific treatment protocols.

More Related Videos

Intravenous Injections in Neonatal Mice05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

61.6K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.6K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
388
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
289
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
344
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
338
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
334